ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag biotech cancer clinical trials business

How Vesselon Can Improve the Entire Class of Radiopharmaceuticals
Clayton Larsen - President & CEO, Vesselon, Inc. | Nov 21, 2023 | 3 min read
Vesselon's microspheres optimize radiopharmaceuticals for targeted treatment, enhancing anti-tumor effects.
Geron’s Stem Cell Program Sold
Jef Akst | Oct 2, 2013 | 2 min read
The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.
Biotech Buys Autoimmune Firm for $7B
Kerry Grens | Jul 16, 2015 | 1 min read
Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.
Cannabis Biotech
Daniel Cossins | Dec 1, 2014 | 8 min read
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates
Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Photograph of scientists working while wearing PPE
Contract Vivarium Facilities for Preclinical Discovery
The Scientist and Mispro | Mar 30, 2023 | 3 min read
Researchers rent contract vivarium space for greater experimental control, productivity, and reproducibility when developing new therapeutics.
Braving the IPO Drought
Megan Scudellari | Mar 1, 2012 | 7 min read
Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

Run a Search

ADVERTISEMENT